generationbio.com - GBIO Forward Price-to-Revenue Multiple
The financial stability of Generation Bio Co. (GBIO) relies on partnerships with industry leaders that guarantee reliable capital. On GURU.Markets, the forward price-to-sales ratio demonstrates asset valuation dynamics, where the 2.30 metric indicates the value status. Patents for synthetic carriers create a steep barrier to entry for competitors, while independence from macroeconomic trends makes the company a defensive asset during recessionary periods.
GBIO (generationbio.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- debt and solvency information:
Debt to Equity Generation Bio Co.|GBIO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Generation Bio|GBIO - Aggregate Debt Obligations|Debts to Book Capitalization GBIO|GBIO - Company Long-Term Liabilities|Company Short-Term Debt Generation Bio|Quick Liquidity Indicator generationbio.com
- financial results and valuation multiples details:
GBIO - Net Financial Result|Projected Future Earnings Generation Bio Co.|GBIO - Market Cap to Net Income Ratio|Forward P/E Multiple Generation Bio|GBIO - Price/Earnings to Growth Ratio|EV/EBITDA Multiple GBIO|GBIO - Operating income before deduction of amortization|Earnings per share for the last twelve months Generation Bio|GBIO - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth generationbio.com|GBIO - Earnings per share growth this year|Net earnings per share growth forecast for next year Generation Bio Co.
- sales revenue and business income indicators:
Summary company analysis:Generation Bio Corp GBIO
Forward P/S measures the market's emotional response to future revenue dynamics, allowing for an assessment of capital freeze risk amid high multiple volatility. The current value of 2.30 in the projected P/S trend reflects Generation Bio Co. (GBIO) lacking pricing power during the R&D stage; however, the potential of its unique non-lipid platform could eventually transform this valuation into a tool for market dominance.
Competitors of Generation Bio Co. (GBIO)
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|QGEN: Market Cap to Projected Revenue|IONS: Forward Price-to-Revenue Multiple|Forward Price to Sales RGEN (Repligen Inc.)|RNA: Forward P/S Multiple|CRSP (crisprtx.com) - Price-to-Projected Revenue Ratio|WGS (GeneDx) - Forward P/S Multiple|Ultragenyx Pharmaceutical Inc. (RARE) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|SRPT - Market Cap to Future Revenue Ratio|Twist Bioscience - Forward Price-to-Revenue Multiple|Forward Price to Sales TXG|Intellia Therapeutics, Inc. - Forward P/S Multiple|Stoke Therapeutics Inc (STOK) - Forward Price-to-Revenue Multiple|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Wave Pharma (WVE)|Forward Price-to-Revenue Multiple MAZE|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PRME|Taysha Gene Therapies Inc (TSHA) - Projected Price to Revenue|Forward P/S Multiple QURE (uniQure Corp)|MeiraGTx Corp - Price-to-Projected Revenue Ratio|REGENXBIO Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio solidbio.com SLDB|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Pacific Biosciences of California, Inc. (PACB)|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Corp)|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|Forward P/S Multiple Korro Bio Inc. KRRO|Editas - Forward P/S Multiple|Projected Price to Revenue Silence Therapeutics Corp (SLN)|PRQR: Forward P/S Multiple|Market Cap to Future Revenue Ratio Codexis (CDXS)|Price-to-Projected Revenue Ratio Sangamo Therapeutics, Inc.|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology Inc)|Forward P/S Multiple MGX|DTIL - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Forward Price to Sales XCUR|Celsion Corporation - Forward P/S Multiple|PHIO - Forward P/S Multiple|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|RNAZ: Price to Expected Revenue Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|IPA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omega OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (syros.com)|TBIO: Forward P/S Multiple|TCON (TRACON Pharmaceuticals Inc.) - Price-to-Projected Revenue Ratio|UBX (Unity Bio) - Forward P/S Multiple
